Marsh projects 8.2% jump in US employer health benefit costs for 2027
- Marsh projects US employer health benefit costs will rise 8.2% in 2027, the highest increase since 2003.
- Without intervention, employers expect current plan costs to increase by 11% on average.
- 59% of employers plan cost-cutting measures, likely shifting more expenses to employees via higher premiums and deductibles.
- GLP-1 medication utilization accounts for one full percentage point of the overall 2027 cost growth.
- 58% of large employers prioritize guiding members to higher-quality care, up from fifth place last year.

*this image is generated using AI for illustrative purposes only.
Marsh (NYSE: MRSH) projects that total health benefit costs per employee for US employers will rise 8.2% on average in 2027. This marks the highest annual increase since 2003 and the fifth consecutive year of elevated growth following a decade of more moderate increases.
The preliminary results from Marsh’s 2026 National Survey of Employer-Sponsored Health Plans, based on responses from over 1,800 employers, indicate significant pressure on corporate budgets. Without intervention, employers expect current plan costs to surge by 11%.
Cost Drivers and Market Dynamics
Several factors are pushing medical cost trends above general inflation. Sunit Patel, Marsh’s US Chief Actuary for Health and Benefits, identified continued advances in diagnostics and therapeutics as a primary driver. While these treatments improve outcomes, they often cost more than the therapies they replace. Additionally, health system consolidation and lower government funding for public health programs are driving higher charges within employer plans.
Newer factors have emerged to push cost growth to levels not seen in decades:
- GLP-1 medications: Rising utilization of weight management drugs accounts for a full percentage point of the overall 2027 cost growth. Some employers seeking immediate relief have dropped this coverage.
- AI-enabled billing: Rapid adoption of AI software for claims submission has resulted in more claims being filed, including higher-level claims for reimbursement.
- No Surprises Act: Larger-than-expected payments to out-of-network providers through the Independent Dispute Resolution process are adding to costs.
Employer Response and Employee Impact
The pressure on healthcare budgets is likely to result in higher costs for employees in 2027. The survey found that 59% of employers plan to implement cost-cutting changes to health benefits, such as higher deductibles that increase members’ out-of-pocket expenses.
A separate Marsh survey conducted earlier this year revealed that about two-thirds of large employers (those with 500 or more employees) expect to increase employees’ share of premium costs next year. Consequently, many employees will see paycheck deductions for health coverage rise by more than the overall average cost increase of 8.2%.
Strategic Shifts in Plan Design
While many employers are shifting costs, others are exploring ways to control spending without burdening employees. Over a third of large employers plan to offer non-traditional medical plans in 2027, such as variable copay or high-performance network plans. These options typically feature lower deductibles and charge members less when they select top-performing providers.
Variable copay plans are gaining traction, with 12% of large employers planning to offer them in 2027. Among employers with 20,000 or more employees, this figure rises to 18%.
Guiding members to higher-quality care is becoming a priority. In the National Survey, 58% of large employers indicated that this strategy would be important or very important, up from fifth place in last year’s survey. Managing high-cost claims remains the highest priority, particularly as expensive new therapies for cancer and rare diseases reach the market.
What the Numbers Show
The divergence between the projected 8.2% cost increase and the 11% unchecked cost rise highlights the effectiveness of employer interventions but also underscores the severity of underlying inflation. With GLP-1 drugs alone contributing one full percentage point to the 8.2% total, specialized therapeutic utilization is now a quantifiable, material component of aggregate healthcare inflation, distinct from general medical trend rates.
How might the rapid adoption of variable copay plans impact the market share and pricing power of high-performance healthcare providers?
What long-term effects could the exclusion of GLP-1 coverage by some employers have on employee health outcomes and future chronic disease management costs?
Could regulatory scrutiny increase regarding AI-enabled billing practices if claims volume continues to outpace actual service utilization?































